Information Library
Results for: Flexible outsourcing - Lower portfolio & investment risks
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Capital - sharing risks, expanding opportunities
Brochure — July 14, 2010
This Capital brochure reviews how Quintiles helps biopharma allies maximize the value of assets, reduce risk, accelerate outcomes and increase rewards. -
Vital Insights
Case Study — June 8, 2010
Quintiles conducted an exhaustive analysis into global and U.S. responses to the use of comparative effectiveness research, identifying key signals to help the customer recognize risk scenarios. -
QUINTILES AND ALLERGAN ANNOUNCE CO-PROMOTION AGREEMENT
Press Release — September 25, 2009 – Quintiles Transnational Corp. and Allergan, Inc. announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR®.
-
Rebalancing Risk to Transform R&D
White Paper — June 3, 2009
A strategic approach to re-balancing the main components of biopharma company risk: portfolio, operational and resource. -
Adrian McKemey, Ph.D.
Hear from the Experts — March 25, 2009
Adrian leads the Product Development and Commercialization consulting practice at Quintiles Global Consulting. -
Jim Featherstone, Ph.D.
Hear from the Experts — March 25, 2009
Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice. -
Jay Norman
Hear from the Experts — March 24, 2009
President – Quintiles Consulting Jay brings 25 years of experience in the consulting industry and a strong track record of growth, most recently with Diamond Management and Technology Consultants, where he served as President and Chief Operating Officer. -
Podcast: A New Gold Standard
Hear from the Experts — May 1, 2008
John Doyle discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.
Page 1 of 1 (8 results)
